What the FDA labels say about taking them together
Amoxapine and tranylcypromine
Tranylcypromine's FDA label of July 2, 2025 names amoxapine in its boxed warning section; amoxapine's label does not name tranylcypromine itself but warns about its class (MAO inhibitors). The tranylcypromine label: “Other monoamine oxidase inhibitors (MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Other antidepressants Amphetamines and …”
Check it at the source: the amoxapine FDA label on DailyMed (effective December 18, 2024, Chartwell RX, LLC); the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.).
What does the amoxapine label say about tranylcypromine?
Amoxapine's label does not name tranylcypromine itself; it warns about its class (MAO inhibitors):
Amoxapine label, contraindicationsHyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressants and monoamine oxidase inhibitors simultaneously.
Amoxapine label, contraindicationsIt should not be given concomitantly with monoamine oxidase inhibitors.
Source: FDA drug label (Amoxapine), Chartwell RX, LLC, effective December 18, 2024 (SPL set eed5e856-dd7b-4eaa-9dad-508f2bef9328), via openFDA; the full label on DailyMed
What does the tranylcypromine label say about amoxapine?
Tranylcypromine label, boxed warningSee, "What is the most important information I should know about PARNATE?” and “What are the possible side effects of PARNATE?” Do not take PARNATE if you: take certain medicines, including: antidepressants, such as: other monoamine oxidase inhibitors (MAOIs) selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine.
Tranylcypromine label, contraindicationsOther monoamine oxidase inhibitors (MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Other antidepressants (e.g., amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine) Amphetamines and methylphenidates and derivatives Sympathomimetic products (e.g., cold, hay fever or weight reducing products that contain vasoconstrictors such as pseudoephedrine, phenylephrine, and ephedrine; …
Tranylcypromine label, drug interactionsProduct: Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine; Clinical Comment on Concomitant Use a: Contraindicated a; Predominant Effect/Risk [Hypertensive Reaction (HR) b or Serotonin Syndrome (SS) c ]: SS for all antidepressants For MAOIs, increased MAO inhibition and risk of adverse reactions, SS, and HR g
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amoxapine | Tranylcypromine | |
|---|---|---|
| Labeled for | Depression, Anxiety | Depression |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.591 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once